CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

Item request has been placed! ×
Item request cannot be made. ×
  Processing Request
  • Additional Information
    • Publication Information:
      BMC, 2006.
    • Publication Date:
      2006
    • Collection:
      LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    • Abstract:
      Abstract Background Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer. Methods We retrospectively investigated the role of CA 15-3 in conjunction with other clinico-pathological variables as a predictor of response and time to disease recurrence following treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3 together with other variables were reviewed and related to four outcomes following primary chemotherapy (clinical response, pathological response, time to recurrence and time to progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels above the cut off point during and after PC. Results 73 patients were included in this study. Patients received PC (AC or AC-T regimen) for locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days. Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (p = 0.013) and pathological (p = 0.044) response. Together with Her-2/neu expression (p = 0.009) and tumour lympho-vascular space invasion (LVI) (p = 0.001), a persistently elevated CA 15-3 post PC (p = 0.007) was an independent predictive factor of recurrence following treatment in LABC. Conclusion Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition, persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular invasion and HER2 status predict a reduced disease free survival following treatment in locally advanced breast cancer.
    • File Description:
      electronic resource
    • ISSN:
      1471-2407
    • Relation:
      http://www.biomedcentral.com/1471-2407/6/220; https://doaj.org/toc/1471-2407
    • Accession Number:
      10.1186/1471-2407-6-220
    • Rights:
      Journal Licence: CC BY
    • Accession Number:
      edsdoj.88d726acb2e4177b1757292ef5d808e
  • Citations
    • ABNT:
      MCDERMOTT ENDA W et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, [s. l.], n. 1, p. 220, 2006. DOI 10.1186/1471-2407-6-220. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.88d726acb2e4177b1757292ef5d808e&custid=s6224580. Acesso em: 15 dez. 2019.
    • AMA:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;(1):220. doi:10.1186/1471-2407-6-220.
    • APA:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, Al-azawi Dhafir, Hill Arnold DK, Duffy Michael J, & Higgins Niall O. (2006). CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, (1), 220. https://doi.org/10.1186/1471-2407-6-220
    • Chicago/Turabian: Author-Date:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, Al-azawi Dhafir, Hill Arnold DK, Duffy Michael J, and Higgins Niall O. 2006. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer, no. 1: 220. doi:10.1186/1471-2407-6-220.
    • Harvard:
      McDermott Enda W et al. (2006) ‘CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer’, BMC Cancer, (1), p. 220. doi: 10.1186/1471-2407-6-220.
    • Harvard: Australian:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, Al-azawi Dhafir, Hill Arnold DK, Duffy Michael J & Higgins Niall O 2006, ‘CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer’, BMC Cancer, no. 1, p. 220, viewed 15 December 2019, .
    • MLA:
      McDermott Enda W, et al. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer, no. 1, 2006, p. 220. EBSCOhost, doi:10.1186/1471-2407-6-220.
    • Chicago/Turabian: Humanities:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, Al-azawi Dhafir, Hill Arnold DK, Duffy Michael J, and Higgins Niall O. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer, no. 1 (2006): 220. doi:10.1186/1471-2407-6-220.
    • Vancouver/ICMJE:
      McDermott Enda W, Myers Eddie, Kelly Gabrielle, Al-azawi Dhafir, Hill Arnold DK, Duffy Michael J, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer [Internet]. 2006 [cited 2019 Dec 15];(1):220. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.88d726acb2e4177b1757292ef5d808e&custid=s6224580